Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 0.32
MELA's Cash to Debt is ranked lower than
76% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.21 vs. MELA: 0.32 )
Ranked among companies with meaningful Cash to Debt only.
MELA' s 10-Year Cash to Debt Range
Min: 0.32  Med: 10000.00 Max: No Debt
Current: 0.32
Equity to Asset 0.50
MELA's Equity to Asset is ranked lower than
64% of the 181 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.60 vs. MELA: 0.50 )
Ranked among companies with meaningful Equity to Asset only.
MELA' s 10-Year Equity to Asset Range
Min: 0.37  Med: 0.64 Max: 0.94
Current: 0.5
0.37
0.94
F-Score: 2
Z-Score: -5.91
M-Score: 55.03
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -1578.58
MELA's Operating margin (%) is ranked lower than
98% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.48 vs. MELA: -1578.58 )
Ranked among companies with meaningful Operating margin (%) only.
MELA' s 10-Year Operating margin (%) Range
Min: -8174.46  Med: -3159.61 Max: -869.05
Current: -1578.58
-8174.46
-869.05
Net-margin (%) -1706.46
MELA's Net-margin (%) is ranked lower than
98% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.54 vs. MELA: -1706.46 )
Ranked among companies with meaningful Net-margin (%) only.
MELA' s 10-Year Net-margin (%) Range
Min: -8155.76  Med: -3193.47 Max: -1085.71
Current: -1706.46
-8155.76
-1085.71
ROE (%) -171.36
MELA's ROE (%) is ranked lower than
93% of the 182 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.29 vs. MELA: -171.36 )
Ranked among companies with meaningful ROE (%) only.
MELA' s 10-Year ROE (%) Range
Min: -233.02  Med: -89.73 Max: -53.54
Current: -171.36
-233.02
-53.54
ROA (%) -85.92
MELA's ROA (%) is ranked lower than
95% of the 193 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.43 vs. MELA: -85.92 )
Ranked among companies with meaningful ROA (%) only.
MELA' s 10-Year ROA (%) Range
Min: -502.58  Med: -86.82 Max: -50.87
Current: -85.92
-502.58
-50.87
ROC (Joel Greenblatt) (%) -287.93
MELA's ROC (Joel Greenblatt) (%) is ranked lower than
88% of the 191 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 11.56 vs. MELA: -287.93 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
MELA' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -4892.42  Med: -1406.56 Max: -243.81
Current: -287.93
-4892.42
-243.81
EBITDA Growth (3Y)(%) -37.80
MELA's EBITDA Growth (3Y)(%) is ranked lower than
94% of the 128 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.70 vs. MELA: -37.80 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
MELA' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0  Med: -12.00 Max: -1
Current: -37.8
EPS Growth (3Y)(%) -27.70
MELA's EPS Growth (3Y)(%) is ranked lower than
90% of the 126 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.70 vs. MELA: -27.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
MELA' s 10-Year EPS Growth (3Y)(%) Range
Min: -28.9  Med: -8.90 Max: 34.6
Current: -27.7
-28.9
34.6
» MELA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

MELA Guru Trades in

Q4 2014

MELA Guru Trades in Q4 2014

Jim Simons 32,064 sh (New)
» More
Q1 2015

MELA Guru Trades in Q1 2015

Jim Simons 61,550 sh (+91.96%)
» More
Q2 2015

MELA Guru Trades in Q2 2015

Jim Simons 25,540 sh (-58.51%)
» More
» Details

Insider Trades

Latest Guru Trades with MELA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 59.88
MELA's Forward P/E is ranked lower than
87% of the 75 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 21.74 vs. MELA: 59.88 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 0.34
MELA's P/B is ranked higher than
99% of the 178 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.91 vs. MELA: 0.34 )
Ranked among companies with meaningful P/B only.
MELA' s 10-Year P/B Range
Min: 0.3  Med: 2.53 Max: 6.36
Current: 0.34
0.3
6.36
P/S 5.99
MELA's P/S is ranked lower than
78% of the 190 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.67 vs. MELA: 5.99 )
Ranked among companies with meaningful P/S only.
MELA' s 10-Year P/S Range
Min: 5.74  Med: 51.62 Max: 1330
Current: 5.99
5.74
1330
Current Ratio 0.81
MELA's Current Ratio is ranked lower than
96% of the 185 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.41 vs. MELA: 0.81 )
Ranked among companies with meaningful Current Ratio only.
MELA' s 10-Year Current Ratio Range
Min: 0.81  Med: 10.29 Max: 25.52
Current: 0.81
0.81
25.52
Quick Ratio 0.60
MELA's Quick Ratio is ranked lower than
94% of the 185 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.60 vs. MELA: 0.60 )
Ranked among companies with meaningful Quick Ratio only.
MELA' s 10-Year Quick Ratio Range
Min: 0.6  Med: 10.21 Max: 25.52
Current: 0.6
0.6
25.52
Days Inventory 170.51
MELA's Days Inventory is ranked lower than
71% of the 183 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 128.59 vs. MELA: 170.51 )
Ranked among companies with meaningful Days Inventory only.
MELA' s 10-Year Days Inventory Range
Min: 60.42  Med: 265.15 Max: 403.31
Current: 170.51
60.42
403.31
Days Sales Outstanding 1.00
MELA's Days Sales Outstanding is ranked higher than
99% of the 161 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 63.01 vs. MELA: 1.00 )
Ranked among companies with meaningful Days Sales Outstanding only.
MELA' s 10-Year Days Sales Outstanding Range
Min: 38.82  Med: 87.76 Max: 236.33
Current: 1
38.82
236.33

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 4.14
MELA's Price/Tangible Book is ranked higher than
54% of the 157 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.27 vs. MELA: 4.14 )
Ranked among companies with meaningful Price/Tangible Book only.
MELA' s 10-Year Price/Tangible Book Range
Min: 0.59  Med: 4.13 Max: 18.29
Current: 4.14
0.59
18.29
Price/Median PS Value 0.12
MELA's Price/Median PS Value is ranked higher than
99% of the 166 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.15 vs. MELA: 0.12 )
Ranked among companies with meaningful Price/Median PS Value only.
MELA' s 10-Year Price/Median PS Value Range
Min: 0.12  Med: 1.01 Max: 21.03
Current: 0.12
0.12
21.03
Earnings Yield (Greenblatt) (%) -76.83
MELA's Earnings Yield (Greenblatt) (%) is ranked lower than
98% of the 184 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.90 vs. MELA: -76.83 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
MELA' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -384.7  Med: 1117.70 Max: 39368.8
Current: -76.83
-384.7
39368.8

Analyst Estimate

Dec15 Dec16 Dec17 Dec18
Revenue(Mil) 18 42 49 57
EPS($) -2.21 0.02 0.07 0.13
EPS without NRI($) -2.21 0.02 0.07 0.13

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, BAX, COV, TMO, COO » details
Traded in other countries:E2ON.Germany,
Mela Sciences Inc was incorporated in the State of New York in December 1989 under the name Electro-Optical Sciences, Inc. and subsequently reincorporated under the laws of the State of Delaware in 1997. In April 2010, it changed its name to MELA Sciences, Inc. The Company is a medical device company focused on the commercialization of its flagship product, MelaFind, the further design and development of MelaFind and its technology. MelaFind is a non-invasive, point-of-care instrument to aid in the detection of melanoma. The MelaFind system produces a report at the point-of-care to assist in the diagnostic process. MelaFind employs light of multiple wavelengths to obtain data from clinically atypical lesions; and then the data are analyzed against its proprietary database of melanomas and benign lesions using its sophisticated algorithms. The Company competes with other imaging modalities, including molecular imaging in which tagged antibodies search for cancer cell antigens, and with molecular and genetic screening tests. The sale and marketing of MelaFind is subject to a complex system of federal and state laws and regulations intended to deter, detect, and respond to fraud and abuse in the healthcare system.
» More Articles for MELA

Headlines

Articles On GuruFocus.com
own Mar 20 2013 
The Barclays Triggers More Insider Buying Mar 13 2013 
ElectroOptical Sciences Inc Reports Operating Results (10-K) Mar 03 2011 
ElectroOptical Sciences Inc Reports Operating Results (10-Q) Nov 05 2010 
ElectroOptical Sciences Inc (MELA) CFO Richard I Steinhart buys 1,000 Shares Aug 12 2010 
ElectroOptical Sciences Inc (MELA) CEO Joseph V Gulfo buys 5,000 Shares Aug 12 2010 
ElectroOptical Sciences Inc (MELA) CEO Joseph V Gulfo buys 5,000 Shares Aug 12 2010 
ElectroOptical Sciences Inc Reports Operating Results (10-Q) Aug 06 2010 
ElectroOptical Sciences Inc Reports Operating Results (10-Q) May 10 2010 
ElectroOptical Sciences Inc Reports Operating Results (10-Q) Nov 09 2009 

More From Other Websites
MELA SCIENCES, INC. /NY Financials Aug 27 2015
10-Q for MELA Sciences, Inc. Aug 16 2015
MELA SCIENCES, INC. /NY Files SEC form 10-Q, Quarterly Report Aug 14 2015
MELA Sciences Reports Second Quarter 2015 Financial Results Aug 13 2015
MELA Sciences Inc Earnings Call scheduled for 4:30 pm ET today Aug 13 2015
MELA SCIENCES, INC. /NY Files SEC form 8-K, Results of Operations and Financial Condition Aug 13 2015
MELA Sciences Reports Second Quarter 2015 Financial Results Aug 13 2015
Q2 2015 MELA Sciences Inc Earnings Release - After Market Close Aug 13 2015
MELA Sciences to Report Second Quarter Financial Results on Thursday, August 13 Aug 12 2015
MELA Sciences to Report Second Quarter Financial Results on Thursday, August 13 Aug 12 2015
MELA SCIENCES, INC. /NY Files SEC form 8-K/A, Completion of Acquisition or Disposition of Assets,... Aug 04 2015
MELA SCIENCES, INC. /NY Files SEC form 8-K, Other Events Aug 03 2015
MELA SCIENCES, INC. /NY Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in... Jul 21 2015
Exclusive: N.Y. medical device firm moving to Montco Jul 15 2015
Montco skin care company sells laser treatment business for $42.5M Jun 23 2015
MELA Sciences Acquires XTRAC and VTRAC Businesses From PhotoMedex, Inc. Jun 23 2015
How MELA Plans to Buy XTRAC and VTRAC From PhotoMedex Jun 23 2015
MELA SCIENCES, INC. /NY Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion... Jun 23 2015
MELA Sciences Acquires XTRAC and VTRAC Businesses From PhotoMedex, Inc. Jun 23 2015
3 Stocks Under $10 Making Big Moves Jun 16 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK